Search Results

ENOblock (AP-III-a4) 5mg 5mg  | Purity Not Available

Adooq Bioscience

ENOblock (AP-III-a4) is a novel small molecule which is the first, nonsubstrate analogue that directly binds to enolase and inhibits its activity (IC50=0.576 uM); inhibit cancer cell metastasis in vivo.

More Information Supplier Page

ENOblock (AP-III-a4) 2mg 2mg  | Purity Not Available

Adooq Bioscience

ENOblock (AP-III-a4) is a novel small molecule which is the first, nonsubstrate analogue that directly binds to enolase and inhibits its activity (IC50=0.576 uM); inhibit cancer cell metastasis in vivo.

More Information Supplier Page

ENOblock (AP-III-a4) 10mg 10mg  | Purity Not Available

Adooq Bioscience

ENOblock (AP-III-a4) is a novel small molecule which is the first, nonsubstrate analogue that directly binds to enolase and inhibits its activity (IC50=0.576 uM); inhibit cancer cell metastasis in vivo.

More Information Supplier Page

Cabazitaxel 50mg 50mg  | Purity Not Available

Adooq Bioscience

Cabazitaxel is a semi-synthetic derivative of a natural taxoid. Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment

More Information Supplier Page

Cabazitaxel 250mg 250mg  | Purity Not Available

Adooq Bioscience

Cabazitaxel is a semi-synthetic derivative of a natural taxoid. Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment

More Information Supplier Page

Cabazitaxel 10mM * 1mL in DMSO 10mM * 1mL in DMSO  | Purity Not Available

Adooq Bioscience

Cabazitaxel is a semi-synthetic derivative of a natural taxoid. Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment

More Information Supplier Page